Procollagen type III N-terminal peptide (P3NP) and lean mass: a cross-sectional study
Boston University, Department of Mathematics and Statistics, 111 Cummington St., Boston, MA 02115 (PG)
The journal of fraility & aging
Procollagen type III N-terminal peptide (P3NP) is released during collagen synthesis in muscle. Increased circulating P3NP is a marker not only of muscle growth, but also of muscle repair and fibrosis. Thus, P3NP may be a potential biomarker for sarcopenia.
To determine the association between plasma P3NP and lean mass and strength.
A cross-sectional study of men and women from the Framingham Offspring Study. Participants included a convenience sample of 687 members with a measure of plasma P3NP and lean mass, and 806 members with P3NP and quadriceps strength assessment.
Linear regression was used to estimate the association between total and appendicular lean mass and plasma P3NP, and quadriceps strength and P3NP.
Mean age was 58 years. Median plasma P3NP was similar in men (3.4 mg/L), premenopausal women (3.1 mg/L), and postmenopausal women (3.0 mg/L). In adjusted models, higher P3NP was associated with a modest decrease in total and appendicular lean mass in postmenopausal women [β= -0.13 unit P3NP/kg total lean mass; p=0.003]. A similar trend was found among premenopausal women, although results were not statistically significant [β=-0.10 unit P3NP/kg total lean mass; p=0.41]. No association between P3NP and lean mass was observed in men. P3NP was not associated with strength in men or women.
Our results suggest that plasma P3NP might be a useful biomarker of muscle mass in postmenopausal women if longitudinal studies demonstrate that it has adequate sensitivity and specificity to predict muscle loss.
Available from: Emanuele Marzetti
[Show abstract] [Hide abstract]
ABSTRACT: Physical frailty (PF) and sarcopenia are two common and largely overlapping geriatric conditions upstream of the disabling cascade. The lack of a unique operational definition for PF and sarcopenia and the complex underlying
pathophysiology make the development of biomarkers for these conditions extremely challenging. Indeed, the current definitional ambiguities of PF and sarcopenia, together with their heterogeneous clinical manifestations, impact the accuracy, specificity and sensitivity of individual biomarkers proposed so far. In this review, the
current state of the art in the development of biomarkers for PF and sarcopenia is presented. A novel approach for biomarker identification and validation is also introduced that moves from the “one fits all” paradigm to a multivariate methodology.
Available from: Etienne Cavalier
[Show abstract] [Hide abstract]
ABSTRACT: We tested and validated irisin (IRI), myostatin (MYO), PIIINP, osteoglycin (OGN), TMEM119 (TMEM) and activin A (AA) and established the analytical performance, reference range and stability (considered unstable if more than 20% increase/decrease in the levels was observed in more than 10% of the samples). We were unable to obtain a valuable calibration curve with the Cusabio kits (TMEME and OGN). Coefficient of variation (CV) was too high for IRI (CV 17-30%), but were. ≤. 10% for the 3 other analytes. AA and MYO were stable up to 3. months at -20. °C and -80. °C in serum or EDTA plasma and up to 6. months at -80. °C. PIIINP was stable only 1. month in EDTA plasma (but not in serum) at -20. °C or -80. °C. After 3. months of storage, PIIINP was not stable anymore, in serum or EDTA plasma, at -20. °C or -80. °C. Surprisingly, after 6. months at -80. °C, results returned in the. ±. 20% for both serum and EDTA plasma. PIIINP levels did not differ between men and women and the RR was (median, 90% CI) 1.2 (0.8-1.6)-6.0 (5.6-6.4). μg/L. The RR for MYO was 845 (437-1312)-6067 (5524-6552). pg/mL for men and 600 (268-1027)-4438 (4026-4837). pg/mL for women and the RR for AA was 177 (132-210)-622 (580-661). pg/mL for men and 98 (49-147)-480 (430-525). pg/mL for women. PIIINP and AA but not MYO accumulated in CKD as values observed in 10 hemodialyzed patients were higher than in normal individuals.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.